(Q46511487)

22 December 2017

title

Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients (English)

1 reference

22 December 2017

1 reference

P T Loh

1

1 reference

22 December 2017

H X Lou

2

1 reference

22 December 2017

Y Zhao

3

1 reference

22 December 2017

Y M Chin

4

1 reference

22 December 2017

A Vathsala

5

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

22 December 2017

Transplantation Proceedings

published in

1 reference

22 December 2017

volume

40

1 reference

22 December 2017

issue

5

1 reference

22 December 2017

page(s)

1690-1695

1 reference

22 December 2017

Pharmacogenomics: translating functional genomics into rational therapeutics

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

The role of individual human cytochromes P450 in drug metabolism and clinical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.010

10.1016/J.TRANSPROCEED.2008.04.010

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

18589174

1 reference

22 December 2017